Invesco
CASC

Invesco’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Invesco’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-4,626
Closed -$35K – 3760
2016
Q1 		$35K Buy
+4,626
New +$35.6K ﹤0.01% 3683
2015
Q3 		– Sell
-235
Closed -$5K – 4172
2015
Q2 		$5K Buy
+235
New +$3.72K ﹤0.01% 4254

Other funds holding CASC

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Invesco's CASC Position: Q2 2016 in Review

Invesco sold out of Cascadian Therapeutics, Inc. (CASC) in Q2 2016, closing a stake of 4,626 shares — an estimated $35K sold.

Invesco first reported a position in CASC in Q2 2015 and held it in 2 quarters. The position peaked at $35K in Q1 2016. 75 funds tracked by Wall St. Rank hold CASC as of Q2 2016.

  • Invesco reported no remaining Cascadian Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • Invesco sold 4,626 Cascadian Therapeutics, Inc. shares in Q2 2016, an estimated $35K.
  • Invesco first reported a position in Cascadian Therapeutics, Inc. in Q2 2015 and held it in 2 quarters.
  • Invesco's Cascadian Therapeutics, Inc. position peaked at $35K in Q1 2016.
  • 75 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2016.

Based on Invesco's 13F filing for Q2 2016, filed 15 Aug 2016.